Mussallem Michael A's Form 4 filing
Edwards Lifesciences Corp (EW) · filed Oct 14, 2022
- Accession no.
- 0001225208-22-010970
- Filed
- Oct 14, 2022
- Trade date
- Oct 14, 2022
- Filing delay
- Same day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 7 non-derivative transactions and 1 derivative transaction. Open-market sales total $1.65M. It was filed on the trade date.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Mussallem Michael ACIK 0001204551 | Director, Officer (Chairman & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2022 | Common Stock | MOption exerciseAcquired | +29,375 | $35.20 | +$1,034,000 | 186,727.82 | Direct | |
| Oct 14, 2022 | Common Stock | SSaleDisposed | −600 | $85.28F2 | −$51,168 | 186,127.82 | Direct | |
| Oct 14, 2022 | Common Stock | SSaleDisposed | −1,800 | $84.64F3 | −$152,352 | 184,327.82 | Direct | |
| Oct 14, 2022 | Common Stock | SSaleDisposed | −2,978 | $83.38F4 | −$248,305.64 | 181,349.82 | Direct | |
| Oct 14, 2022 | Common Stock | GGiftDisposed | −9,500 | $0.00 | $0 | 171,849.82 | Direct | |
| Oct 14, 2022 | Common Stock | SSaleDisposed | −14,497 | $82.41F5 | −$1,194,697.77 | 157,352.82 | Direct | |
| Oct 14, 2022 | Common Stock | GGiftAcquired | +9,500 | $0.00 | $0 | 3,454,017 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2022 | Common Stock | MOption exerciseDisposed | −29,375 | $0.00 | $0 | 205,625 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $85.070 to $85.775 The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $84.020 to $85.000. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $82.950 to $83.910. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
- F5
This transaction was executed in multiple trades at prices ranging from $81.920 to $82.750. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.